Xiaohui Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaohui Xia has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Chen Gong
Department of Oncology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
1 shared publication - Huihua Xiong
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
1 shared publication - Yinan Zhang
School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China
1 shared publication
Latest Publications
- Open Access
- 12 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1450
The History and Development of HER2 Inhibitors
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.
- 12 October 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (10) , 1450
Open AccessThe History and Development of HER2 Inhibitors
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.